A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
This study has been terminated.
( Terminated due to unfavorable human pharmacokinetic properties )
Study NCT01332552
Information provided by GlaxoSmithKline
First Received on April 7, 2011.
Last Updated on December 1, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
